We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

135 hedge funds and large institutions have $265M invested in Rigel Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 33 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

58% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 33

13% more capital invested

Capital invested by funds: $234M → $265M (+$30.7M)

7% more funds holding

Funds holding: 126 → 135 (+9)

0.27% less ownership

Funds ownership: 8.87% → 8.6% (-0.27%)

10% less call options, than puts

Call options by funds: $44K | Put options by funds: $49K

Holders
135
Holders Change
+9
Holders Change %
+7.14%
% of All Funds
2.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
52
Reduced
33
Closed
8
Calls
$44K
Puts
$49K
Net Calls
-$5K
Net Calls Change
-$2K

Top Buyers

1
BlackRock
BlackRock
New York
+$4.2M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.89M
3
TA
Tamarack Advisers
California
+$2.34M
4
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$1.99M
5
JGC
J. Goldman & Co
New York
+$1.32M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$13.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.07M
3
Goldman Sachs
Goldman Sachs
New York
-$3.42M
4
Morgan Stanley
Morgan Stanley
New York
-$2.07M
5
SI
Sofinnova Investments
California
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
JGC
26
J. Goldman & Co
New York
$1.88M +$1.32M +73,405 +251%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$1.85M +$1.09M +60,525 +150%
PAM
28
Panagora Asset Management
Massachusetts
$1.75M +$99.6K +5,535 +6%
Los Angeles Capital Management
29
Los Angeles Capital Management
California
$1.72M +$711K +39,537 +72%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$1.57M +$84.9K +4,720 +6%
Two Sigma Investments
31
Two Sigma Investments
New York
$1.42M +$501K +27,866 +56%
N
32
Nuveen
North Carolina
$1.4M +$289K +16,059 +27%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.25M -$6.21K -345 -0.5%
Canada Pension Plan Investment Board
34
Canada Pension Plan Investment Board
Ontario, Canada
$1.22M +$1.2M +66,900 New
Russell Investments Group
35
Russell Investments Group
United Kingdom
$1.15M +$298K +16,579 +36%
Millennium Management
36
Millennium Management
New York
$1.03M -$13.7M -759,970 -93%
AC
37
Armistice Capital
New York
$957K +$940K +52,270 New
WMSA
38
Weiss Multi-Strategy Advisers
New York
$912K +$30.6K +1,700 +4%
Charles Schwab
39
Charles Schwab
California
$763K +$24.6K +1,369 +3%
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
$754K +$157K +8,737 +27%
JP Morgan Chase
41
JP Morgan Chase
New York
$740K -$414K -23,025 -36%
Swiss National Bank
42
Swiss National Bank
Switzerland
$700K +$111K +6,190 +19%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$687K +$1.44K +80 +0.2%
Squarepoint
44
Squarepoint
New York
$670K +$433K +24,048 +191%
SI
45
Sofinnova Investments
California
$622K -$1.99M -110,662 -77%
AG
46
Artal Group
Luxembourg
$619K -$21.6K -1,200 -3%
Goldman Sachs
47
Goldman Sachs
New York
$598K -$3.42M -189,905 -85%
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$475K – – –
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$465K – – –
Barclays
50
Barclays
United Kingdom
$456K +$72.9K +4,050 +19%
1
2
3 4 5

RIGL Hedge Fund Activity: Q2 2020 in Review

135 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2020, worth a combined $265M — up 13% from $234M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RIGL positions and 8 closed out — a net gain of 10 holders — while 52 added to existing stakes and 33 trimmed.

The largest buyer was BlackRock, adding an estimated $4.2M. The largest seller was Millennium Management, cutting an estimated $13.7M.

  • 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2020, up from 126 in Q1 2020.
  • Funds reported $265M of Rigel Pharmaceuticals stock for Q2 2020, up 13% quarter-over-quarter.
  • 18 funds opened new Rigel Pharmaceuticals positions in Q2 2020 and 8 closed out, a net change of +10 holders.
  • The largest Rigel Pharmaceuticals buyer in Q2 2020 was BlackRock, an estimated $4.2M added.
  • The largest Rigel Pharmaceuticals seller in Q2 2020 was Millennium Management, an estimated $13.7M sold.

Based on aggregated 13F filings for Q2 2020.